Haleon is a public company limited by shares, incorporated under the laws of England and Wales with registered number of 13691224. The Company has ordinary shares with a nominal value of £0.01 per share. The Group’s shares are listed and traded on the London Stock Exchange (LSE) with American Depositary Shares (ADSs) listed on the New York Stock Exchange (NYSE) (LSE/NYSE: HLN). The registered address of the Company is Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY, United Kingdom.
Company profile
Ticker
HLN
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
DRVW 2022 Ltd
SEC CIK
Corporate docs
HLN stock data
Latest filings (excl ownership)
6-K
Appointment of Dawn Allen As CFO
24 Apr 24
6-K
Notice of Annual General Meeting (Agm)
12 Apr 24
6-K
Director/pdmr Shareholding
3 Apr 24
6-K
Total Voting Rights and Capital
2 Apr 24
25-NSE
Exchange delisting
25 Mar 24
6-K
Holding(s) In Company
22 Mar 24
6-K
Current report (foreign)
21 Mar 24
6-K
Total Voting Rights and Capital
21 Mar 24
6-K
Closing of Secondary Global Offering by Pfizer
21 Mar 24
6-K
Final Prospectus Supplement Filed with the Sec
20 Mar 24
Latest ownership filings
SC 13D/A
PFIZER INC
22 Mar 24
SC 13D/A
PFIZER INC
19 Mar 24
SC 13D/A
GSK plc
19 Jan 24
SC 13D/A
PFIZER INC
19 Jan 24
144
Notice of proposed sale of securities
29 Dec 23
144
Notice of proposed sale of securities
5 Dec 23
144
Notice of proposed sale of securities
3 Nov 23
SC 13D/A
PFIZER INC
10 Oct 23
SC 13D/A
GSK plc
10 Oct 23
SC 13D/A
GSK plc
11 Sep 23
Financial summary
Quarter (USD) | Dec 22 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Annual (USD) | Dec 22 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Institutional ownership, Q3 2023
95.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 550 |
Opened positions | 66 |
Closed positions | 69 |
Increased positions | 172 |
Reduced positions | 165 |
13F shares | Current |
---|---|
Total value | 3.25 tn |
Total shares | 4.35 bn |
Total puts | 162.90 k |
Total calls | 250.80 k |
Total put/call ratio | 0.6 |
Largest owners | Shares | Value |
---|---|---|
PFE Pfizer | 2.96 bn | $0.00 |
GSK GSK | 1.01 bn | $0.00 |
Dodge & Cox | 109.40 mm | $911.28 bn |
FMR | 53.95 mm | $449.42 bn |
Clearbridge Advisors | 25.97 mm | $216.33 bn |
Harding Loevner | 22.48 mm | $187.28 bn |
Fisher Asset Management | 15.16 mm | $126.32 bn |
Alliancebernstein | 10.77 mm | $89.70 bn |
Bain Capital Public Equity Management II | 10.18 mm | $84.80 bn |
JTC Employer Solutions Trusteee | 9.32 mm | $77.68 bn |
News
Haleon Appoints Dawn Allen As CFO, After Tobias Hestler Announced To Step Down; Dawn Will Join Haleon On 28 October And Will Assume The Role Of CFO From 1 November
24 Apr 24
Argus Research Maintains Buy on Haleon, Maintains $10 Price Target
26 Mar 24
Pfizer To Cut Stake In Sensodyne Toothpaste-Maker Haleon, Potentially Worth £2B
18 Mar 24
Advil Maker Haleon Expects Higher 2024 Revenue After Strong 2023 Earnings, Stock Soars
29 Feb 24
Earnings Scheduled For February 29, 2024
29 Feb 24